We distribute our research widely to institutional and retail investors through various channels, including our proprietary database, website, and other platforms (such as Bloomberg, Thomson Reuters and Factset).
We are fully MiFID II compliant. Our research is paid for by our corporate clients, and we do not carry out any execution business.
Published reports can be obtained by searching our Research Library below, or directly from the relevant Company Pages.
Bonesupport
A second consecutive quarter of record revenueHutchison China MediTech
Acceptance of surufatintib China NDA in epNETMereo BioPharma
Setrusumab set to advanceMaxCyte
Third cohort in CARMA Phase I initiatedNexstim
Warrants to be topped up with share placementNexstim
Q319 update shows therapy business momentumNexstim
A possible new opportunity in severe depressionMaxCyte
Editas deal marks sixth commercial licenceHutchison China MediTech
ESMO 2019: surufatinib epNET PFS benefit confirmedMereo BioPharma
Entering an important 12 month period